Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Pfizer Has High Hopes for Elrexfio/Prevenar 20, Rich ADC Assets after Seagen Deal
June 13, 2024
- Lilly Set to Raise Profile as Only Eczema Player with Oral and Injectable Options
June 13, 2024
- Astellas’ Gastric Cancer Drug Vyloy Now Available in Japan
June 13, 2024
- Ono Completes Acquisition of Deciphera
June 13, 2024
- En Route to 2030 Target, Shionogi to Carve Out New Biz in Areas with High Medical Needs
June 12, 2024
- Otsuka Resolved to Log 2.5 Trillion Yen in FY2028 by Offsetting Patent Cliffs with Novel Drugs
June 12, 2024
- Kyowa Kirin to Build Biologics Manufacturing Site in North Carolina
June 12, 2024
- Maruho Launches Mitchga 30 mg Vial Version in Japan
June 12, 2024
- US FDA Snubs Mitsubishi Tanabe’s Parkinson’s Drug
June 12, 2024
- Takeda Rebuts ISS’ Advice to Vote against Re-Election of CEO Weber
June 11, 2024
- Susana Murteira Tapped as Amgen Japan President
June 11, 2024
- Alecensa Snags EU OK for Adjuvant Setting of ALK-Positive NSCLC
June 11, 2024
- Japan Ethical Drug Sales Up 7.3% in April: Crecon
June 11, 2024
- Keytruda Tops Japan Drug Sales Ranking for 8 Months on End: Encise
June 11, 2024
- Takeda Rolls Out Obizur for Acquired Hemophilia A in Japan
June 11, 2024
- Kissei Grants Korean Rights for GnRH Antagonist Linzagolix to JW
June 11, 2024
- Leqembi’s Monthly IV Dosing Accepted for FDA Review: Eisai
June 11, 2024
- Moderna Files Updated Spikevax for JN.1 Strain in Japan
June 11, 2024
- Rohto Bags Majority Stake in Austria Pharma to Boost European Biz
June 10, 2024
- Towa Files NDA for Rivastigmine Twice Weekly Transdermal Patch in Japan
June 10, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…